SZLSF (StageZero Life Sciences) Buyback Yield % : -9.60 (As of Dec. 14, 2024)

View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

StageZero Life Sciences's current buyback yield was -9.60%.

StageZero Life Sciences Buyback Yield % Historical Data

The historical data trend for StageZero Life Sciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Buyback Yield % Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Buyback Yield %

Get a 7-Day Free Trial

-18.35

-50.42

-26.89

-14.87

-33.03

StageZero Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24
Buyback Yield %	Get a 7-Day Free Trial															-	-19.78	-1.53	-	-

Competitive Comparison of StageZero Life Sciences's Buyback Yield %

For the Diagnostics & Research subindustry, StageZero Life Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Buyback Yield % falls into.

StageZero Life Sciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

StageZero Life Sciences's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	1.543)	/	4.6720995
	=	-33.03%

StageZero Life Sciences's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	0.1852995
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2024) data.

StageZero Life Sciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.